FDA’s Woodcock Cautions Efforts To 'Legislate A New Generation Of Biomarkers'

New approaches to biomarker qualification is big part of industry’s agenda for '21st Century Cures,' but CDER Director Janet Woodcock remains concerned about efforts to legislate ahead of the science.